For Investors

At Delix, we are paving the way in neuroplasticity research, and every day is an opportunity to change the lives of people living with neurological conditions.

Our scientific team is pioneering the development of third-generation, non-hallucinogenic neuroplastogens, and we have more than 1500 compounds in our portfolio with 2 candidates entering the clinic this year and multiple programs swiftly following behind.

Our pipeline is built on a discovery platform that identifies assets that are rapid, sustained, convenient, and scalable—the backbone for pushing neurological treatment into the future.